Spectrum Pharma rises on launch of neutropenia drug
21/10/2022 12:58
** Shares of Spectrum Pharmaceuticals Inc SPPI.O up ~13%
at 43 cents premarket
** Co announces commercial availability of its injection,
Rolvedon urn:newsml:reuters.com:*:nBw5Tjhk0a
** The drug, which received U.S. FDA approval last month, is
meant to decrease incidence of neutropenia in cancer patients
receiving myelosuppressive therapies like chemotherapy and
radiation urn:newsml:reuters.com:*:nL4N30G32E
** Neutropenia is characterized by decrease in the number of
white blood cells and is common after receiving chemotherapy
** As of last close, stock was down ~70% YTD
(Reporting by Raghav Mahobe)
((Raghav.Mahobe@thomsonreuters.com;))
Recent news on Spectrum Pharmaceuticals
See all newsBrief: Assertio Holdings Announces Favorable Vote On Proposed Acquisition Of Spectrum Pharmaceuticals
Brief: Independent Proxy Advisory Firms ISS And Glass Lewis Recommend Spectrum Pharmaceuticals Stockholders Vote “For” Proposed Deal With Assertio Holdings, Inc.
Brief: Spectrum Pharmaceuticals Regains Compliance With Nasdaq Minimum Bid Price Requirement
U.S. RESEARCH ROUNDUP-CTI Biopharma, Park National, Playags
Spectrum Pharmaceuticals Inc reports results for the quarter ended in March - Earnings Summary